In Part B ( dose finding ) , 151 patients were randomised to sirukumab ( 100mg q2w , 100mg q4w , 50mg q4w , or 25mg q4w ) through week 24 , or placebo through week 10 with crossover to sirukumab 100mg q2w ( weeks 12-24 ) .